NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
Clinical Trials
141 trialsNCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT05257590 2026-04-13
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT07521852 2026-04-13
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
NCT03916627 2026-04-06
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT06096779 2026-04-03
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT05733598 2026-04-02
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune Inc.
Phase 2 Recruiting
NCT05063565 2026-03-27
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
NCT07052253 2026-03-16
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Akeso
Phase 2 Recruiting
NCT05432492 2026-03-04
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Akeso
Phase 2 Completed
NCT05441475 2026-02-25
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Abbisko Therapeutics Co, Ltd
Phase 2 Enrolling by invitation
NCT02519348 2026-02-17
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT03463876 2026-02-17
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT06330064 2026-02-12
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
Phase 2 Recruiting
NCT06953089 2026-02-06
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 2 Recruiting
NCT05641896 2026-01-22
18F-FAPI-74 GI
SOFIE
Phase 2 Completed
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT04567615 2026-01-08
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Bristol-Myers Squibb
Phase 2 Completed
NCT07327034 2026-01-08
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Abbisko Therapeutics Co, Ltd
Phase 2 Recruiting
NCT07324304 2026-01-07
NWRD06 DNA Plasmid for HCC After Curative Resection.
Newish Technology (Beijing) Co., Ltd.
Phase 2 Recruiting
NCT07081633 2025-12-30
TREMENDOUS-2
AstraZeneca
Phase 2 Recruiting
NCT07310173 2025-12-30
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 2 Recruiting
NCT05879822 2025-12-17
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Incyte Corporation
Phase 2 Active not recruiting
NCT07239986 2025-11-20
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
Broadenbio Ltd., Co.
Phase 2 Not yet recruiting
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT07219459 2025-10-21
GDFATHERHCC01
CatalYm GmbH
Phase 2 Not yet recruiting
NCT07209813 2025-10-07
GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma
Beijing Gene Key Life Technology Co., Ltd
Phase 2 Not yet recruiting
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05822752 2025-08-14
LIVIGNO-1
AbbVie
Phase 2 Active not recruiting
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT06984718 2025-05-22
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
Akeso
Phase 2 Not yet recruiting
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT04000737 2025-04-13
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
Yiviva Inc.
Phase 2 Completed
NCT04629339 2025-03-13
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
Phase 2 Terminated
NCT05864105 2025-03-12
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Biotheus Inc.
Phase 2 Active not recruiting
NCT04401800 2025-03-10
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
BeiGene
Phase 2 Completed
NCT05195294 2025-03-10
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Lion TCR Pte. Ltd.
Phase 2 Not yet recruiting
NCT06742892 2025-03-10
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
Shanghai Henlius Biotech
Phase 2 Recruiting
NCT04710641 2025-03-06
OUTREACH2
Mina Alpha Limited
Phase 2 Completed
NCT05304481 2025-03-06
Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Lukas Biomedical Inc.
Phase 2 Recruiting
NCT05653427 2025-01-13
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT06349980 2024-12-18
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Shanghai Henlius Biotech
Phase 2 Recruiting
NCT06558227 2024-12-16
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Recruiting
NCT06724263 2024-12-09
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Tasly Biopharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT03145558 2024-11-22
TATE
Teclison Ltd.
Phase 2 Terminated
NCT01101906 2024-11-20
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Astellas Pharma Inc
Phase 2 Terminated